f) Binding of 100
nM ECDHER2 to immobilized hDM-αH-C6.5 MH3B1 after incubation with 1 μM hDM-αH-C6.5 MH3B1. (B), Binding of biotinylated hDM-αH-C6.5 MH3B1 to ECDHER2 expressed on the cell surface. Bound buy Emricasan protein was detected using Streptavidin-PE. Left panel shows binding of 0.5 μg of biotinylated hDM-αH-C6.5 MH3B1 to CT26HER2/neu and not to the parental cells that lack HER2/neu expression. Right panel shows binding of 0.1 μg (heavy green), or 0.5 μg of biotinylated hDM-αH-C6.5 MH3B1 (thin blue) or Streptavidin-PE (heavy black) to MCF-7HER2 cells. Filled are unstained cells. hDM in hDM-αH-C6.5 MH3B1 can target cytotoxic activity to HER2/neu expressing cells To determine if hDM-αH-C6.5 MH3B1 activity LY3023414 can be specifically targeted to HER2/neu expressing cells, fusion protein was incubated at room temperature for 45 minutes with CT26HER2/neu, the parental CT26 cells that lack the expression of HER2/neu or MCF-7HER2. The unbound protein was washed away, 1.5 μM or 6 μM of F-dAdo added, and after 72 hours the amount of cell proliferation was determined by MTS. hDM-αH-C6.5 MH3B1 was found to remain bound to HER2/neu expressing cells, causing a dose dependent inhibition of cell
proliferation in the presence of F-dAdo as a consequence of its conversion to F-Ade. No cytotoxicity was seen with CT26 cells that did not express HER2/neu (Fig. 5A). For CT26HER2/neu and MCF-7HER2 cells the IC50 for hDM-αH-C6.5 MH3B1 was 0.0196 μM and 0.0254 μM, respectively. Gemcitabine In summary, enzymatic activity of hDM-αH-C6.5 MH3B1 remains associated with HER2/neu expressing cells and causes cleavage of F-dAdo to F-Ade resulting in dose dependent inhibition of cell proliferation. Figure 5 hDM-αH-C6.5 MH3B1 specifically associates with
HER2/ neu expressing cells and causes cytotoxicty in the presence of F-dAdo irrespective of expression of tumor antigen or cell growth rate. (A), hDM-αH-C6.5 MH3B1 associates with HER2/neu expressing cells resulting in concentration dependent cytotoxicity upon addition of 1.5 or 6 μM F-dAdo to CT26HER2/neu or MCF-7HER2 cells respectively. Different concentrations of hDM-αH-C6.5 MH3B1 were incubated with cells, unbound enzyme washed away, F-dAdo added and 72 hours later cellular Methisazone proliferation was determined by MTS assay. (B), CT26HER2/neu and CT26 cells were seeded at different ratios and grown overnight. hDM-αH-C6.5 MH3B1 was incubated with cells for 45 minutes, and washed away. Cells were then grown in the presence of 1.5 μM F-dAdo for 72 hours and cell proliferation determined by MTS assay. (C), MCF-7HER2 cells were grown overnight (O/N) in the presence of 10% serum, washed and growth continued for 72 hours in the presence of varying amounts of serum. The column labeled overnight (O/N) represents the number of cells prior to switching to different amounts of serum.